Drug News

Elon Musk’s Ongoing Drug Use Sparks Boardroom Shockwaves

The Wall Street Journal has reported concerns among executives and board members at companies led by Elon Musk regarding his drug use. According to unidentified sources familiar with Musk and the companies he runs, the billionaire has been using LSD, cocaine, ecstasy, psychedelic mushrooms, and, more recently, ketamine. Witnesses and insiders, who chose to remain unnamed, disclosed that Musk often consumes these substances at private parties.

The Tesla Inc. and SpaceX CEO’s drug use is said to be ongoing, with Musk claiming in August that he has a prescription for ketamine as an antidepressant. Notably, Musk faced scrutiny in 2018 after smoking marijuana on Joe Rogan’s podcast. This incident prompted a review of his federal security clearance by the Pentagon, given his role as the CEO of Space Exploration Technologies Corp., which is authorized to launch military spy satellites.

In response to the recent allegations, Musk posted on his social media platform, X, stating that, following the incident on Rogan’s podcast, he agreed to three years of random drug testing at NASA’s request. He emphasized that no trace quantities of any drugs or alcohol were found in his system during these tests.

Alex Spiro, an attorney representing Musk, told the Wall Street Journal that Musk undergoes regular and random drug testing at SpaceX and has never failed a test. Spiro referred to “false facts” in the article without providing specific details.

The report also mentioned that Linda Johnson Rice, who served as a Tesla director from 2017, did not seek reelection two years later, expressing frustration with Musk’s behavior and concerns about his drug use. Despite these concerns, Musk continues to oversee six companies, including Tesla, SpaceX, X (formerly Twitter), The Boring Co., Neuralink, and xAI, with a net worth of $219.4 billion, securing his position as the wealthiest individual according to the Bloomberg Billionaires Index.


Joan David-Leonhard

Joan David Leonhard is a recent Pharm.D graduate with a strong passion for the pharmaceutical industry and a particular interest in pharmaceutical media and communication. Her brief internship experience includes roles in pharmacy where she built strong patient-pharmacist relationships and a pharmaceutical media internship where she actively contributed to drug information articles, blog posts, social media engagement, and various media projects.
Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker